Literature DB >> 21826685

Regulation of the calpain and ubiquitin-proteasome systems in a canine model of muscular dystrophy.

Kristine M Wadosky1, Luge Li, Jessica E Rodríguez, Jin-Na Min, Dan Bogan, Jason Gonzalez, Cam Patterson, Joe N Kornegay, Monte Willis.   

Abstract

INTRODUCTION: Previous studies have tested the hypothesis that calpain and/or proteasome inhibition is beneficial in Duchenne muscular dystrophy, based largely on evidence that calpain and proteasome activities are enhanced in the mdx mouse.
METHODS: mRNA expression of ubiquitin-proteasome and calpain system components were determined using real-time polymerase chain reaction in skeletal muscle and heart in the golden retriever muscular dystrophy model. Similarly, calpain 1 and 2 and proteasome activities were determined using fluorometric activity assays.
RESULTS: We found that less than half of the muscles tested had increases in proteasome activity, and only half had increased calpain activity. In addition, transcriptional regulation of the ubiquitin-proteasome system was most pronounced in the heart, where numerous components were significantly decreased.
CONCLUSION: This study illustrates the diversity of expression and activities of the ubiquitin-proteasome and calpain systems, which may lead to unexpected consequences in response to pharmacological inhibition.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21826685      PMCID: PMC3175337          DOI: 10.1002/mus.22125

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  59 in total

1.  Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition.

Authors:  M A Badalamente; A Stracher
Journal:  Muscle Nerve       Date:  2000-01       Impact factor: 3.217

2.  Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition.

Authors:  Daisuke Tamura; Tokuzo Arao; Kaoru Tanaka; Hiroyasu Kaneda; Kazuko Matsumoto; Kanae Kudo; Keiichi Aomatsu; Yoshihiko Fujita; Takashi Watanabe; Nagahiro Saijo; Yoshikazu Kotani; Yoshihiro Nishimura; Kazuto Nishio
Journal:  Cancer Sci       Date:  2010-03-15       Impact factor: 6.716

3.  Muscular dystrophy in a litter of golden retriever dogs.

Authors:  J N Kornegay; S M Tuler; D M Miller; D C Levesque
Journal:  Muscle Nerve       Date:  1988-10       Impact factor: 3.217

Review 4.  The heart in human dystrophinopathies.

Authors:  Josef Finsterer; Claudia Stöllberger
Journal:  Cardiology       Date:  2003       Impact factor: 1.869

5.  Identification of ubiquitin ligases required for skeletal muscle atrophy.

Authors:  S C Bodine; E Latres; S Baumhueter; V K Lai; L Nunez; B A Clarke; W T Poueymirou; F J Panaro; E Na; K Dharmarajan; Z Q Pan; D M Valenzuela; T M DeChiara; T N Stitt; G D Yancopoulos; D J Glass
Journal:  Science       Date:  2001-10-25       Impact factor: 47.728

Review 6.  Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review.

Authors:  B A Valentine; N J Winand; D Pradhan; N S Moise; A de Lahunta; J N Kornegay; B J Cooper
Journal:  Am J Med Genet       Date:  1992-02-01

7.  The cranial sartorius muscle undergoes true hypertrophy in dogs with golden retriever muscular dystrophy.

Authors:  Joe N Kornegay; Diane D Cundiff; Daniel J Bogan; Janet R Bogan; Carol S Okamura
Journal:  Neuromuscul Disord       Date:  2003-08       Impact factor: 4.296

8.  Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology.

Authors:  Melissa J Spencer; Ronald L Mellgren
Journal:  Hum Mol Genet       Date:  2002-10-01       Impact factor: 6.150

9.  The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs.

Authors:  B J Cooper; N J Winand; H Stedman; B A Valentine; E P Hoffman; L M Kunkel; M O Scott; K H Fischbeck; J N Kornegay; R J Avery
Journal:  Nature       Date:  1988-07-14       Impact factor: 49.962

10.  Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins.

Authors:  Gloria Bonuccelli; Federica Sotgia; William Schubert; David S Park; Philippe G Frank; Scott E Woodman; Luigi Insabato; Michael Cammer; Carlo Minetti; Michael P Lisanti
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

View more
  9 in total

Review 1.  Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies.

Authors:  Joe N Kornegay; Janet R Bogan; Daniel J Bogan; Martin K Childers; Juan Li; Peter Nghiem; David A Detwiler; C Aaron Larsen; Robert W Grange; Ratna K Bhavaraju-Sanka; Sandra Tou; Bruce P Keene; James F Howard; Jiahui Wang; Zheng Fan; Scott J Schatzberg; Martin A Styner; Kevin M Flanigan; Xiao Xiao; Eric P Hoffman
Journal:  Mamm Genome       Date:  2012-01-05       Impact factor: 2.957

2.  Neuroprotective Effect of Calpeptin on Acrylamide-Induced Neuropathy in Rats.

Authors:  Xiaomin Wei; Fengfeng Yan; Meng E; Cuili Zhang; Guozhen Li; Xiwei Yang; Fengmei Zhang; Shue Wang; Sufang Yu
Journal:  Neurochem Res       Date:  2015-09-30       Impact factor: 3.996

Review 3.  Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials.

Authors:  Joe N Kornegay; Christopher F Spurney; Peter P Nghiem; Candice L Brinkmeyer-Langford; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  ILAR J       Date:  2014

4.  The ubiquitin ligase tripartite-motif-protein 32 is induced in Duchenne muscular dystrophy.

Authors:  Stefania Assereto; Rosanna Piccirillo; Serena Baratto; Paolo Scudieri; Chiara Fiorillo; Manuela Massacesi; Monica Traverso; Luis J Galietta; Claudio Bruno; Carlo Minetti; Federico Zara; Elisabetta Gazzerro
Journal:  Lab Invest       Date:  2016-06-13       Impact factor: 5.662

5.  Genetic myostatin decrease in the golden retriever muscular dystrophy model does not significantly affect the ubiquitin proteasome system despite enhancing the severity of disease.

Authors:  Steven W Cotten; Joe N Kornegay; Daniel J Bogan; Kristine M Wadosky; Cam Patterson; Monte S Willis
Journal:  Am J Transl Res       Date:  2013-12-01       Impact factor: 4.060

Review 6.  The golden retriever model of Duchenne muscular dystrophy.

Authors:  Joe N Kornegay
Journal:  Skelet Muscle       Date:  2017-05-19       Impact factor: 4.912

7.  Orai1 mediates exacerbated Ca(2+) entry in dystrophic skeletal muscle.

Authors:  Xiaoli Zhao; Joseph G Moloughney; Sai Zhang; Shinji Komazaki; Noah Weisleder
Journal:  PLoS One       Date:  2012-11-19       Impact factor: 3.240

8.  Bortezomib (PS-341) treatment decreases inflammation and partially rescues the expression of the dystrophin-glycoprotein complex in GRMD dogs.

Authors:  Karla P C Araujo; Gloria Bonuccelli; Caio N Duarte; Thais P Gaiad; Dayson F Moreira; David Feder; José E Belizario; Maria A Miglino; Michael P Lisanti; Carlos E Ambrosio
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

9.  Calpain-mediated proteolysis of tropomodulin isoforms leads to thin filament elongation in dystrophic skeletal muscle.

Authors:  David S Gokhin; Matthew T Tierney; Zhenhua Sui; Alessandra Sacco; Velia M Fowler
Journal:  Mol Biol Cell       Date:  2014-01-15       Impact factor: 4.138

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.